Terns Pharmaceuticals

Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Pharma Voice
Thu, 02/27/25 - 10:12 am
Terns Pharmaceuticals
MASH
obesity
oncology
Obesity pill race heats up as Novo, Roche and Terns share data
BioSpace
Tue, 09/17/24 - 11:22 am
obesity
Novo Nordisk
Roche
Terns Pharmaceuticals
amycretin
TERN-601
CT-996
clinical trials
Terns Pharmaceuticals' oral obesity drug shows promise in early study, shares jump
Reuters
Mon, 09/9/24 - 11:29 am
Terns Pharmaceuticals
obesity
clinical trials
5 Obesity Readouts to Watch in the Second Half of 2024
BioSpace
Tue, 08/13/24 - 11:47 am
obesity
clinical trials
Novo Nordisk
CagriSema
Amgen
MariTide
Monlunabant
Aphaia Pharma
APHD-012
Terns Pharmaceuticals
TERN-601
Pfizer's obesity pill news leaves analysts wanting, biotech investors cheering
Fierce Biotech
Fri, 07/12/24 - 11:14 am
Pfizer
obesity
danuglipron
Viking Therapeutics
Terns Pharmaceuticals
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
Wed, 08/23/23 - 10:06 am
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
Thu, 08/10/23 - 09:54 am
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
IPO tracker: 2021 gets started with a flurry of new offerings
Endpoints
Mon, 01/25/21 - 10:43 am
IPOs
Sana Biotechnology
Sensei Biotherapeutics
Bolt Biotherapeutics
Immunocore
Terns Pharmaceuticals
Pharvaris
Vor Biopharma
Adagene
NexImmune
Biophytis
Gracell Biotechnologies
Cullinan Oncology
Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic
Endpoints
Tue, 01/5/21 - 10:03 am
NASH
Terns Pharmaceuticals
Eli Lilly
FDA grants fast track status to Terns’s FXR agonist to treat NASH
Pharmaceutical Business Review
Wed, 10/30/19 - 10:01 am
Terns Pharmaceuticals
FDA
NASH
TERN-101
fast track